Development

Type 2 diabetes is a reversible condition

A body of research putting people with Type 2 diabetes on a low calorie diet has confirmed the underlying causes of the condition and established that it is reversible. Professor Roy Taylor at Newcastle University, UK has spent almost four decades studying the condition and will present an overview of his findings at the European Association For The Study Of Diabetes (EASD 2017) in Lisbon.

CAREFOR calls on EU to safeguard independent academic research

Three leading European organisations in the fight against cancer have called the EU to urgently increase its support for independent academic research for the benefit of cancer patients, in an article published in ESMO Open (1). CAREFOR (the Clinical Academic Cancer Research Forum) is a joint initiative by the European Association for Cancer Research (EACR), the European Organisation for the Research and Treatment of Cancer (EORTC), and the European Society for Medical Oncology (ESMO).

A project that studies chronic systemic inflammation receives EU funding

Erwin Wagner, Director of the Cancer Cell Biology Programme at the Spanish National Cancer Research Centre (CNIO), has been awarded an Advanced Grant from the European Research Council (ERC) to study Chronic Systemic Inflammation, a major health problem that causes morbidity and mortality associated with pathologies of the immune system and cancer.

The Royal Swedish Academy of Sciences urges Hungarian lawmakers to refrain from restricting scientific freedom

The Hungarian parliament is seeking new legislation that could endanger academic freedom and educational quality. It could also lead to the closure of one of the universities in Budapest. The leaders of The Royal Swedish Academy of Sciences now make a public statement, urging the parliament not to restrict scientific freedom.

Your computer can help scientists search for new childhood cancer treatments

Medical researchers and IBM (NYSE: IBM) are asking the public's help in finding prospective treatments for childhood cancers, the top worldwide cause of death by disease for children. Scientists are searching for chemical drug candidates that can affect the key molecules and proteins that control cancer cells in several common childhood cancers. However, finding drug candidates is an expensive and slow process.

€29m research grant to assess risk posed by deadly lung infections

Experts have received €29 million (£24m) to investigate serious lung infections that particularly affect babies and older people. Diseases caused by respiratory syncytial virus (RSV) are estimated to affect more than 30 million children under five each year throughout the world. The virus also affects older people and those with weakened immune systems, including cancer patients and people with chronic lung diseases such as emphysema.